日本传染病疫苗纳入常规免疫规划的问题及加速流程的考量
本文基于日本健康科学理事会免疫与疫苗委员会的公开数据,探讨已批准疫苗纳入常规免疫规划所需信息及流程耗时长的原因。识别出的讨论要点包括疾病负担、效力与安全性、成本效果。罕见严重不良反应频率及加强针必要性的流行病学信息获取耗时较长。鉴于决策延迟可能增加传染病传播风险,作者提出可基于短期内可获得的临床试验结果引入疫苗,同时急需建立流行病学信息收集系统。
要点
- 已批准疫苗纳入日本常规免疫规划可能耗时长达十年。
- 讨论要点包括疾病负担、效力与安全性、成本效果。
- 罕见严重不良反应频率和加强针必要性的流行病学信息获取耗时较长。
核心结论
- 决策延迟可能增加传染病传播风险,疫苗或可基于短期内可获得的临床试验结果纳入常规免疫规划。
- 评估疾病负担、不良反应频率和加强针必要性需要流行病学信息,因此急需建立流行病学信息收集系统。
研究设计与样本
- 基于日本健康科学理事会免疫与疫苗委员会已发表数据,探讨已批准疫苗纳入常规免疫规划所需信息及流程耗时长的原因。
主要发现
- 在日本,从疫苗批准到纳入常规免疫规划可能耗时长达十年。
- 识别出的讨论要点为疾病负担、效力与安全性、成本效果。
- 某些情况下,获取罕见但严重不良反应频率及加强针必要性的流行病学信息耗时较长。
关键数值与推荐
- 讨论要点包括疾病负担、效力与安全性、成本效果。
临床怎么用
- 作者提出,鉴于决策延迟可能增加传染病传播风险,疫苗或可基于短期内可获得的临床试验结果纳入常规免疫规划。
- 作者认为,评估疾病负担、不良反应频率和加强针必要性需要流行病学信息,因此急需建立流行病学信息收集系统。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Routine vaccinations help prevent the outbreak and spread of infectious diseases; however, it can take up to ten years from vaccine approval to introduction into routine vaccination schedules in Japan. Here, we investigate the information required to introduce an approved vaccine into routine vaccination schedules and the reasons why it takes so long. Based on the published data of the Immunization and Vaccine Committee of the Health Science Council, we set out to explore ways to facilitate discussion on this topic. The following issues were identified as discussion points: disease burden, efficacy and safety, and cost-effectiveness. Until now, epidemiological information has been used to evaluate the efficacy of vaccines, and also to evaluate the safety in the presence of notable adverse reactions. However, in some cases, it took a long time to obtain epidemiological information regarding the frequency of rare but serious adverse reactions and the need for a booster dose. Given the risk of spreading infectious diseases due to delays in decision-making, vaccines may have to be introduced into routine vaccination schedules based on the results of clinical trials that can be obtained in a relatively short period. In contrast, epidemiological information is necessary to evaluate the disease burden, frequency of adverse reactions, and the necessity of booster doses. Therefore, developing an epidemiological information collection system is urgently required.
引用
- Okumoto A, Nomura Y, Okuda S, et al. Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process. Vaccine. 2024. PMID: 38199920. doi:10.1016/j.vaccine.2023.12.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。